OBJECTIVES/HYPOTHESIS: To evaluate the responsiveness of human papillomavirus (HPV) -positive and HPV-negative oropharyngeal cancer to intensity-modulated radiotherapy (IMRT), using axial imaging obtained daily during the course of image-guided radiotherapy (IGRT). STUDY DESIGN: Observational cohort study with matched-pair analysis of patients irradiated for HPV-positive and HPV-negative oropharygeal cancer. METHODS AND MATERIALS: Ten patients treated by IMRT to 70 Gy for locally advanced, HPV-positive squamous cell carcinoma of the oropharynx were matched to one HPV-negative control subject by age, gender, performance status, T-category, tumor location, and the use of concurrent chemotherapy. The gross tumor volume (GTV) was delineated on daily IGRT scans obtained via kilovoltage cone-beam computed tomography (CBCT). Mathematical modeling using fitted mixed-effects repeated measure analysis was performed to quantitatively and descriptively assess the trajectory of tumor regression. RESULTS: Patients with HPV-positive tumors experienced a more rapid rate of tumor regression between day 1 of IMRT and the beginning of week 2 (-33% Δ GTV) compared to their counterparts with HPV-negative tumors (-10% Δ GTV), which was statistically significant (p<0.001). During this initial period, the average absolute change in GTV was -22.9 cc/week for HPV-positive tumors and -5.9 cc/week for HPV-negative tumors (p<0.001). After week 2 of IMRT, the rates of GTV regression were comparable between the two groups. CONCLUSIONS: HPV-positive oropharyngeal cancers exhibited an enhanced response to radiation, characterized by a dramatically more rapid initial regression than those with HPV-negative tumors. Implications for treatment de-intensification in the context of future clinical trials and the possible mechanisms underlying this increased radiosensitivity will be discussed.
OBJECTIVES/HYPOTHESIS: To evaluate the responsiveness of human papillomavirus (HPV) -positive and HPV-negative oropharyngeal cancer to intensity-modulated radiotherapy (IMRT), using axial imaging obtained daily during the course of image-guided radiotherapy (IGRT). STUDY DESIGN: Observational cohort study with matched-pair analysis of patients irradiated for HPV-positive and HPV-negative oropharygeal cancer. METHODS AND MATERIALS: Ten patients treated by IMRT to 70 Gy for locally advanced, HPV-positive squamous cell carcinoma of the oropharynx were matched to one HPV-negative control subject by age, gender, performance status, T-category, tumor location, and the use of concurrent chemotherapy. The gross tumor volume (GTV) was delineated on daily IGRT scans obtained via kilovoltage cone-beam computed tomography (CBCT). Mathematical modeling using fitted mixed-effects repeated measure analysis was performed to quantitatively and descriptively assess the trajectory of tumor regression. RESULTS:Patients with HPV-positive tumors experienced a more rapid rate of tumor regression between day 1 of IMRT and the beginning of week 2 (-33% Δ GTV) compared to their counterparts with HPV-negative tumors (-10% Δ GTV), which was statistically significant (p<0.001). During this initial period, the average absolute change in GTV was -22.9 cc/week for HPV-positive tumors and -5.9 cc/week for HPV-negative tumors (p<0.001). After week 2 of IMRT, the rates of GTV regression were comparable between the two groups. CONCLUSIONS:HPV-positive oropharyngeal cancers exhibited an enhanced response to radiation, characterized by a dramatically more rapid initial regression than those with HPV-negative tumors. Implications for treatment de-intensification in the context of future clinical trials and the possible mechanisms underlying this increased radiosensitivity will be discussed.
Authors: Randall J Kimple; Molly A Smith; Grace C Blitzer; Alexandra D Torres; Joshua A Martin; Robert Z Yang; Chimera R Peet; Laurel D Lorenz; Kwangok P Nickel; Aloysius J Klingelhutz; Paul F Lambert; Paul M Harari Journal: Cancer Res Date: 2013-06-07 Impact factor: 12.701
Authors: John V Hegde; Narek Shaverdian; Megan E Daly; Carol Felix; Deborah L Wong; Michael H Rosove; Jordan H Garst; Pin-Chieh Wang; Darlene Veruttipong; Shyam Rao; Ruben C Fragoso; Jonathan W Riess; Michael L Steinberg; Allen M Chen Journal: Cancer Date: 2017-10-17 Impact factor: 6.860
Authors: Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri Journal: Otolaryngol Head Neck Surg Date: 2014-05-08 Impact factor: 3.497
Authors: Kara S Davis; John A Vargo; Robert L Ferris; Steven A Burton; James P Ohr; David A Clump; Dwight E Heron Journal: Oral Oncol Date: 2014-08-28 Impact factor: 5.337
Authors: R Maquieira; S K Haerle; G F Huber; A Soltermann; S R Haile; S J Stoeckli; Martina A Broglie Journal: Eur Arch Otorhinolaryngol Date: 2015-06-10 Impact factor: 2.503
Authors: Terence T Sio; Pamela J Atherton; Brandon J Birckhead; David J Schwartz; Jeff A Sloan; Drew K Seisler; James A Martenson; Charles L Loprinzi; Patricia C Griffin; Roscoe F Morton; Jon C Anders; Thomas J Stoffel; Robert E Haselow; Rex B Mowat; Michelle A Neben Wittich; James D Bearden; Robert C Miller Journal: Support Care Cancer Date: 2016-04-14 Impact factor: 3.603